The California Institute for Regenerative Medicine (CIRM) funds and provides valuable educational and training opportunities in regenerative medicine for students and young professionals from backgrounds that reflect the diverse communities across California. One of the goals of these work training programs is to inspire the next generation of regenerative medicine scientists. CIRM does that by … Continue reading Ready, set, pitch!
Meet Our New CEO: Jonathan Thomas
We are thrilled to (re)introduce Jonathan Thomas (JT) as the new President and CEO of the California Institute for Regenerative Medicine (CIRM). You can check out the original press release here. We recently sat down with JT –who previously served as Chair of the Independent Citizens’ Oversight Committee (ICOC) as well as interim President and … Continue reading Meet Our New CEO: Jonathan Thomas
Exploring Advances in Eye Disease Webinar
The California Institute for Regenerative Medicine (CIRM) has been at the forefront of advancing cellular and gene therapies for various forms of vision loss—including retinitis pigmentosa (RP)—making significant progress in this critical field. Ongoing research and clinical trials are vital to further these advancements. We invite you to join our webinar, Exploring Advances in Eye Disease … Continue reading Exploring Advances in Eye Disease Webinar
A CIRM Bridges Trainee’s Path into Regenerative Medicine
Josh Nelson, a former technical director for various theaters, tapped into CIRM's Bridges program at Cal Poly Humbolt to establish a career in regenerative medicine research.
A day in the life of SPARK interns
The CIRM-funded Summer Program to Accelerate Regenerative Medicine Knowledge (SPARK) is one of the California Institute for Regenerative Medicine’s (CIRM) many educational programs dedicated to building a diverse and highly skilled workforce to support California's growing regenerative medicine economy. CIRM’s paid summer program offers diverse high school students unique opportunities in stem cell research—particularly … Continue reading A day in the life of SPARK interns
Gene therapy trial tests cancer-killing virus in brain tumors
Dr. Noriyuki Kasahara from UCSF has been awarded $11.8 million by the California Institute for Regenerative Medicine (CIRM) to target newly diagnosed high-grade gliomas. This groundbreaking clinical trial aims to treat high-grade gliomas, one of the most challenging brain cancers to manage. These aggressive cancers develop in the brain or spinal cord and are notoriously … Continue reading Gene therapy trial tests cancer-killing virus in brain tumors
CIRM awards $6 million to advance research for heart attack and heart failure treatments
In a promising development for cardiovascular health, Arjun Deb, MD, a professor of medicine and molecular, cell, and developmental biology at UCLA, has received a $6 million award from the California Institute for Regenerative Medicine (CIRM) to advance his groundbreaking research on heart attack and heart failure treatments. Cardiovascular disease remains the leading cause of … Continue reading CIRM awards $6 million to advance research for heart attack and heart failure treatments
CIRM Welcomes Jonathan Thomas as New President and CEO
The California Institute for Regenerative Medicine (CIRM) is excited to announce the appointment of Jonathan “JT” Thomas, PhD, JD, as our new President and CEO. JT brings extensive experience and a deep commitment to our mission. Previously, he served as the Chair of the Independent Citizens' Oversight Committee (ICOC) for 12 years and, most recently, … Continue reading CIRM Welcomes Jonathan Thomas as New President and CEO
$53 million awarded to fund clinical and translational research
The California Institute for Regenerative Medicine (CIRM) recently awarded $53 million to fund various projects, from its Clinical and Translational programs aimed at preventing heart failure to the advancement of cell therapy for Parkinson’s disease and the targeting of numerous cancers. Two preclinical projects are providing funding for eligible stem cell and gene therapy-based projects … Continue reading $53 million awarded to fund clinical and translational research
Advancing cell therapy research for dry age-related macular degeneration (dry AMD)
The California Institute for Regenerative Medicine (CIRM) granted Luxa Biotechnology a $4 million award to support the ongoing Phase 1/2a study (NCT04627428) of RPESC-RPE-4W transplantation, an innovative therapy for treating dry age-related macular degeneration (dry AMD). The funding will significantly enhance manufacturing and clinical activities in California. Dry AMD is a prevalent eye disorder affecting … Continue reading Advancing cell therapy research for dry age-related macular degeneration (dry AMD)